A. Lorch

发表

The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors

C. Oing, A. Lorch, 2018, Oncology Research and Treatment.

Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients.

T. Hermanns, C. Fankhauser, D. Eberli, 2020, The oncologist.

Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages

G. Kristiansen, D. Beyersdorff, P. Albers, 2021, Urologia Internationalis.

European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update.

E. Compérat, M. Rouanne, R. Cathomas, 2020, European urology oncology.

Primary Urethral Carcinoma EAU Guidelines on

J. Witjes, E. Compérat, M. Rouanne, 2016 .

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.

J. Witjes, E. Compérat, M. Rouanne, 2020, European urology.

Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.

C. Bokemeyer, J. Shamash, C. Fankhauser, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late relapse of germ cell tumors.

S. Fosså, J. Oldenburg, A. Lorch, 2011, Hematology/oncology clinics of North America.

Metastatic Bladder Cancer Disease and Its Treatment

G. Niegisch, A. Lorch, 2018 .

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees.

W. Oyen, T. H. van der Kwast, M. Babjuk, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry.

C. Fankhauser, H. Haugnes, U. de Giorgi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

J. Shamash, P. Hutton, O. Ståhl, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of LDH levels in patients with relapsed/refractory seminoma

T. Powles, C. Bascoul-Mollevi, A. Kramar, 2013, Journal of Cancer Research and Clinical Oncology.

First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database

C. Bokemeyer, K. Oechsle, C. Oing, 2015, Journal of Cancer Research and Clinical Oncology.

Patterns of Relapse after Chemotherapy in Patients with High-Risk Non-Seminomatous Germ Cell Tumor

C. Bokemeyer, K. Oechsle, J. Hartmann, 2010, Oncology.

2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma

R. Huddart, J. Shamash, O. Ståhl, 2015 .

First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)

C. Bokemeyer, T. Gauler, K. Oechsle, 2014, Journal of Cancer Research and Clinical Oncology.

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

J. Droz, A. Kramar, K. Fizazi, 2013 .

Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.

C. Bokemeyer, J. Hartmann, C. Kollmannsberger, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial.

C. Bokemeyer, A. Kramar, O. Rick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How we treat germ cell cancers

J. Beyer, A. Lorch, 2017, Cancer.

Management of Refractory Germ Cell Cancer.

A. Lorch, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[Update on first-line and relapse chemotherapy for testicular cancer].

P. Albers, A. Lorch, 2013, Der Urologe. Ausg. A.

Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome

P. Albers, A. Hiester, J. Schirren, 2020, World Journal of Urology.

Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series

C. Bokemeyer, A. Dieing, C. Oing, 2019, Journal of Cancer Research and Clinical Oncology.

High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how

J. Beyer, A. Lorch, 2017, World Journal of Urology.

The Role of Residual Tumor Resection in the Management of Nonseminomatous Germ Cell Cancer of Testicular Origin

S. Bölükbas, M. Eberlein, J. Schirren, 2012, Thoracic and Cardiovascular Surgeon.

High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.

C. Bokemeyer, J. Hartmann, O. Rick, 2010, The Journal of urology.

Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours

H. Moch, T. Hermanns, C. Fankhauser, 2021, British Journal of Cancer.

Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.

J. Bedke, R. Cathomas, A. Dieing, 2022, The Lancet. Oncology.

High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion

R. Moll, M. Lohoff, J. Beyer, 2018, Oncoimmunology.

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

C. Bokemeyer, T. Gauler, K. Oechsle, 2018, Journal of Cancer Research and Clinical Oncology.

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

R. Huddart, T. Powles, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

J. Droz, A. Kramar, K. Fizazi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST).

P. Albers, C. Arsov, A. Hiester, 2022, European urology.

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

L. Collette, S. Culine, R. Huddart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Muscle-invasive and Metastatic Bladder Cancer EAU Guidelines on

E. Compérat, T. Lebret, G. Gakis, 2016 .

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2021, World Journal of Urology.

Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2020, European journal of cancer.

Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer

M. Pichler, K. Dieckmann, G. Belge, 2020, Cancers.

Renal cell carcinoma pathology in 2021: ‘new need for renal cancer immune profiling’

H. Moch, M. van den Broek, K. Silina, 2021, Current opinion in urology.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

D. Berney, S. Fosså, A. Horwich, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data

T. Hermanns, N. Clarke, C. Fankhauser, 2021, Journal of Cancer Research and Clinical Oncology.

Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data

T. Hermanns, C. Fankhauser, D. Eberli, 2020, Journal of Cancer Research and Clinical Oncology.

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

L. Collette, R. Huddart, C. Bokemeyer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

A. Ravaud, T. Powles, C. Sternberg, 2018 .

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

S. Fosså, A. Horwich, R. Huddart, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Testicular Germ Cell Cancer Patients

R. Souchon, F. Mayer, M. Hartmann, 2011, Oncology Research and Treatment.

Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Early Stage Seminomatous Testicular Germ Cell Cancer Patients

R. Souchon, M. Santis, F. Mayer, 2011, Strahlentherapie und Onkologie.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

T. Powles, C. Bascoul-Mollevi, L. Einhorn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.

M. Milowsky, E. Compérat, J. Efstathiou, 2021, European urology.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

M. Babjuk, T. D. de Reijke, S. Culine, 2019, European urology.

Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

H. Moch, T. Hermanns, C. Fankhauser, 2022, Frontiers in Oncology.

High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors.

C. Bokemeyer, O. Rick, A. Neubauer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

How Should Patients with Recurrent Disease Be Treated Actually

A. Lorch, 2015 .

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

C. Bokemeyer, R. Schirren, W. Berdel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

W. Oyen, M. Babjuk, S. Culine, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[Salvage treatment in germ cell tumors : high-dose chemotherapy and the impact of prognostic factors].

C. Bokemeyer, K. Oechsle, A. Lorch, 2009, Der Urologe. Ausg. A.

The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel.

J. Witjes, Yuhong Yuan, E. Compérat, 2019, European urology oncology.

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.

S. Fosså, A. Horwich, J. Aparicio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort.

F. Mayer, H. Seifert, M. D. De Santis, 2010, Swiss medical weekly.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment

M. Puhan, R. Cathomas, D. Menges, 2023, European urology open science.

Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.

L. Einhorn, A. Necchi, A. Kramar, 2010 .

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

P. Albers, Hugh J. Lavery, G. Niegisch, 2013, European urology.

Prognostic factors in relapsed or refractory male germ cell tumors: Results from an international study of 1,593 patients.

A. Kramar, C. Mollevi, A. Lorch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.

C. Bokemeyer, J. Hartmann, O. Rick, 2010 .

LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10

J. Bedke, R. Cathomas, A. Dieing, 2021, Annals of Oncology.

Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.

T. Hermanns, C. Fankhauser, J. Beyer, 2023, Swiss medical weekly.

A practice-changing step forward in germ-cell cancer?

A. Lorch, 2014, The Lancet. Oncology.

Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.

C. Bokemeyer, K. Oechsle, V. Grünwald, 2016, Urologic oncology.

Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study

R. Gnannt, S. Balabanov, R. Schwotzer, 2023, International journal of cancer.

Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: Analysis of published case series data

T. Hermanns, N. Clarke, C. Fankhauser, 2020 .

Metastasiertes Prostatakarzinom: Neue Erkenntnisse und Entwicklungen

A. Lorch, A. Lorch, 2013, Deutsche Medizinische Wochenschrift.

How we treat germ cell cancers

J. Beyer, A. Lorch, 2017, Cancer.